Head and neck

Head and neck and oropharyngeal cancer updates on ctDNA or MRD testing and coverage.

Jan 1, 2026Head & neck MRD / ctDNA Reimbursement / coverage

MolDX billing article lists MRD coverage for HPV-negative head and neck cancer and for HPV-driven oropharyngeal cancer

The MolDX billing article A58434, in the revision effective January 1, 2026, lists HPV-negative head and neck squamous cell carcinoma among covered indications for recurrence testing with RaDaR, and lists HPV-driven oropharyngeal squamous cell cancer among covered indications for NavDx.

CMS MolDX

Head and neck · MRD Watch